Innovative cancer cell visualization method developed in Dresden revealed

The National Center for Tumor Diseases Dresden (NCT/UCC) is at the forefront of bringing a groundbreaking new technology into application. This technology, developed by a research duo led by Professor Ellen Sletten from UCLA and Oliver Bruns from NCT/UCC Dresden, is revolutionizing surgery in the coming years.

The researchers have created an innovative imaging system that utilizes short-wave infrared light, special fluorescent dyes, and state-of-the-art camera technology. This technology is designed to make malignant cancer cells more visible, particularly in deeper tissue layers where current medical imaging techniques reach their limits.

In combination with these special fluorescent dyes, tissues and structures such as tumors or blood vessels become specifically visible. The development of new contrast agents enables surgeons to recognize tumors more accurately during surgery, preserving as much healthy tissue as possible. Moreover, the technology allows for the determination of different tissue types based on water content.

Clinical studies are currently running in collaboration with Stanford University to document the benefits of this imaging system for patients. The exact name of the clinical study is not specified, but it is clear that this technology has the potential to significantly improve the outcomes for patients undergoing cancer surgery.

The research at NCT/UCC focuses on the development of latest technologies to improve cancer therapy. The duo's work has been honored with the Helmholtz High Impact Award 2024, a testament to its potential impact on the field.

The award ceremony can be found on Youtube for those interested in learning more about this groundbreaking technology and the researchers behind it. The future of cancer surgery looks promising with this new imaging technology on the horizon.